ASH 2013 Annual Meeting

Atlanta, GA—Dutch investigators found that rituximab (Rituxan) maintenance in the second-line treatment of patients with follicular lymphoma (FL) was cost-effective, as reported at the 2012 American Society of Hematology meeting.
Read Article

Atlanta, GA—Ruxolitinib (Jakafi) alleviates symptoms such as fever, headache, weight loss, and fatigue, and reduces spleen size in patients with myelofibrosis.
Read Article

Atlanta, GA—Many patients with multiple myeloma succumb to infection before they have a chance to benefit from cancer therapy, according to a new study from Sweden.
Read Article

Boston, MA—Researchers believe they are closing in on a better way to identify breast cancers that are particularly dangerous and therefore require more aggressive therapy.
Read Article

For the prevention of recurrent venous thromboembolism (VTE), rivaroxaban (Xarelto) appears to be more cost-effective than warfarin (Coumadin), an independent analysis undertaken by the University of Pittsburgh School of Medicine showed.
Read Article

Atlanta, GA—Support for the oral immunomodulatory agent pomalidomide for the treatment of multiple myeloma took a giant step forward when new data from the phase 3 MM-003 trial showed a survival advantage in patients with advanced disease.
Read Article

Atlanta, GA—Promising preliminary results for oprozomib (ONX 0912), an orally available structural analogue of carfilzomib (Kyprolis), were presented at the 2012 American Society of Hematology meeting.
Read Article

Atlanta, GA—MLN9708, an investigational oral proteasome inhibitor, produced impressive results in a phase 1/2 clinical trial of treatment-naïve patients with multiple myeloma that was featured in a press briefing at the 2012 American Society of Hematology (ASH) meeting.
Read Article

A study using real-world data for patients with tumor lysis syndrome (TLS) showed that treatment with rasburicase (Elitek) was associated with significantly greater reductions in uric acid, length of hospital stay, and total hospitalization costs per patient compared with allopurinol (Zyloprim).
Read Article

Atlanta, GA—The investigational agent ibrutinib, which is making news in the treatment of patients with leukemia, demonstrated “unprecedented” single-agent activity in patients with relapsed or refractory mantle-cell lymphoma (MCL), according to the lead author of an international phase 2 study that was reported at the 2012 American Society of Hematology meeting.
Read Article

Page 1 of 2